GlassScriptPhysician profile
Jose M Torres
NPI 1306952403
$3,747.08
in general payments reported to CMS, 2019-2025
30 companies · $750 in 2025
The $750 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $632 · 2021: $361 · 2022: $603 · 2023: $476 · 2024: $427 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,653.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $744.06 | 2020-2025 | Ensite |
| Amarin Pharma, INC. | $364.70 | 2019-2022 | |
| Novo Nordisk INC | $363.29 | 2019-2025 | Ozempic, Wegovy |
| Pfizer INC. | $342.71 | 2019-2025 | |
| Almatica Pharma LLC | $304.48 | 2021-2023 | Loreev Xr, Sertraline Hcl, Gralise |
| Glaxosmithkline, LLC. | $171.96 | 2019-2024 | Shingrix, Arexvy |
| Stryker Corporation | $153.23 | 2024 | Mako |
| Depuy Synthes Sales INC. | $107.69 | 2021-2023 | Na |
| Abbvie INC. | $100.40 | 2021-2024 | Ubrelvy, Synthroid |
| Janssen Pharmaceuticals, INC | $99.28 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $94.56 | 2019-2024 | Jardiance, Zepbound, Mounjaro |
| Exact Sciences Corporation | $93.20 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $85.26 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $81.37 | 2019 | |
| Medtronic, INC. | $80.01 | 2025 | Cobalt Dr Mri Surescan |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.95 | 2020-2023 | Jardiance |
| Allergan, INC. | $76.48 | 2019-2020 | |
| Amgen INC. | $72.90 | 2019-2025 | Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $48.08 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $42.52 | 2019-2025 | Farxiga |
| Phathom Pharmaceuticals, INC. | $40.60 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.09 | 2021-2025 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $25.01 | 2025 | Strensiq |
| Astellas Pharma US INC | $22.02 | 2020 | |
| Genentech USA, INC. | $21.22 | 2020 | |
| Idorsia Pharmaceuticals US INC | $20.92 | 2023 | Quviviq |
| Daiichi Sankyo INC. | $20.72 | 2021 | |
| Phadia US INC. | $19.75 | 2023 | Immunocap |
| Inspire Medical Systems, INC. | $15.91 | 2025 | Inspire |
| Esperion Therapeutics, INC. | $15.71 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.